4
Participants
Start Date
February 20, 2018
Primary Completion Date
January 14, 2019
Study Completion Date
January 14, 2019
Investigational Agent: VL-2397
VL-2397
Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Voriconazole, Isavuconazole, or Liposomal amphotericin B
Jules Bordet Institute, Department of Infectious Disease, Brussels
University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven
General Hospital Saint-Jan, Department of Hematology, Bruges
Christiana Care Health Services, Department of Medicine, Newark
Medical College of Georgia at Augusta University, Augusta
University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham
Grenoble University Hospital Center, Department of Hematology, Grenoble
DMC Harper University Hospital, Detroit
Medical College of Wisconsin, Milwaukee
University of Minnesota, Department of Medicine, Minneapolis
Washington University School of Medicine, Division of Infectious Disease, St Louis
Hautepierre Hospital, Strasbourg
South Lyon Hospital Center, Pierre-Bénite
The University of Texas Health Science Center, Department of Internal Medicine, Houston
Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology, Munich
UC San Diego Moores Cancer Center, La Jolla
UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento
Fred Hutchinson Cancer Research Center (FHCRC), Seattle
University Hospital Antwerp (UZA), Department of Hematology, Edegem
UCL Mont-Godinne University Hospitals, Department of Hematology, Yvoir
Hamilton Health Sciences, Infectious Disease Research, Hamilton
Toronto General Hospital, Toronto
McGill University Health Centre (MUHC), Division of Infectios Diseases, Montreal
University Hospital Jena, Jena
Chonnam National University, Hwasun
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Lead Sponsor
Vical
INDUSTRY